The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Subscribe To Our Newsletter & Stay Updated
